Published in Transplant Res on August 02, 2016
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Matching methods for causal inference: A review and a look forward. Stat Sci (2010) 9.78
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet (1994) 3.56
Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25
Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation (1985) 2.34
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis (2001) 1.68
Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation (2005) 1.62
Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol (2007) 1.51
Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ (2015) 1.49
Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant (2003) 1.43
Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis (1995) 1.39
Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis (1997) 1.23
Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol (2010) 1.22
Feeling manipulated: cytomegalovirus immune manipulation. Virol J (2009) 1.19
An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation (1995) 1.13
The immune response to human CMV. Future Virol (2012) 1.10
Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res (2010) 1.08
Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation (2001) 1.08
Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant (2010) 1.08
Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol (2012) 1.07
Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant (2008) 1.01
New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit (2009) 1.01
Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant (2008) 0.98
Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant (2011) 0.98
The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med (2007) 0.97
Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation (2003) 0.96
Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol (2006) 0.95
Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant (2005) 0.94
Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant (2003) 0.93
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation (1997) 0.92
Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant (2011) 0.91
The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation (2000) 0.90
HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation (2005) 0.90
Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation (2013) 0.89
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma (2008) 0.89
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep (2013) 0.89
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation (2006) 0.88
Borderline rejection after renal transplantation--to treat or not to treat. Clin Transplant (2009) 0.87
Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant (2007) 0.87
Human leukocyte antigens and genetic susceptibility to lymphoma. Tissue Antigens (2015) 0.86
(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int (2012) 0.86
Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant (1999) 0.85
Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Transplantation (2015) 0.85
Update on liver transplantation using cyclosporine. Transplant Proc (2004) 0.84
Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant (2013) 0.83
Value of the SOFA score as a predictive model for short-term survival in high-risk liver transplant recipients with a pre-transplant labMELD score ≥ 30. Langenbecks Arch Surg (2011) 0.82
New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens (2002) 0.81
Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation. Am J Clin Pathol (2005) 0.81
Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens. Drugs (2012) 0.81
Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transpl Int (2000) 0.81
Posttransplant lymphoproliferative disease in liver transplant patients. Curr Infect Dis Rep (2011) 0.80
C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl (2004) 0.80
Clinical Role of Human Leukocyte Antigen in Health and Disease. Scand J Immunol (2015) 0.80
Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation (2011) 0.78
CMV and EBV-PTLD after liver transplantation. Transplant Proc (2001) 0.77
Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient. J Transplant (2011) 0.76